LinkedIn · Oct 2025
Varun Govil announced the first EpiAmp dataset and whitepaper, claiming >99% per-doubling accuracy, faithful 5mC preservation across millions of CpG sites, and compatibility with short-read, long-read, and PCR-based workflows.
We engineer proteins that control the operating system of biology.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Epinoma is a San Carlos-based biotechnology research / diagnostics company developing EpiAmp, a methyl-preserving, conversion-free amplification platform for DNA methylation analysis used in early cancer detection, MRD monitoring, and epigenetic therapeutics. Public funding records are inconsistent across databases, but the clearest source-backed announcement is a $3M seed financing led by SeedToB Capital.
Primary product
EpiAmp methyl-preserving amplification platform
Founded
2020
Headquarters
930 Brittan Avenue, San Carlos, CA 94070, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Epigenetic diagnostics
Offices
San Carlos, California, United States
Santa Clara, California, United States
San Francisco, California, United States
Business model
B2B platform licensing
Custom assay / panel development
Research tools and workflows
Diagnostics enabling technology
Funding
Stage
Seed
Total raised
$3M
Latest round
Seed · Oct 2021
Latest amount
$3M
Oct 2021 · SeedToB Capital
People & investors
Leadership
CEO and Co-Founder
Co-Founder and Chief Operating Officer
Advisor, Product Development Strategy
Founders
Co-Founder
Work & culture
Public careers copy emphasizes a multi-disciplinary, mission-driven scientific team and values of boldness, excellence, integrity, and collaboration; Epinoma also states it is an equal opportunity employer.
Compensation
Public job postings on YC list a Therapeutic Research Associate at $70K-$95K with 0.10%-0.25% equity and a Protein Scientist role at $90K-$125K with 0.25%-1.00% equity; no broader compensation policy is publicly posted.
Product & market
Pricing
Not publicly disclosed; appears to be B2B platform licensing and custom assay development.
Differentiators
- —Methylation-preserving, conversion-free amplification
- —Higher sensitivity than bisulfite / enzymatic workflows
- —Compatible with gDNA, cfDNA, and FFPE samples
- —Single-day turnaround
- —Platform-agnostic across sequencing and PCR readouts
- —Designed for low-input / rare-sample use cases
- —Targets cancer detection, MRD monitoring, and epigenetic medicine workflows
Technology
EpiAmp
methyl-preserving amplification
protein engineering
epigenetics / epigenome assays
gDNA
cfDNA
FFPE
qMSP
EM-seq
WGBS
PCR
NGS
single-cell workflows
TALENs
CRISPR
zinc fingers
protein-DNA interaction assays
Customers
Blood test developers
Liquid biopsy companies
Biopharma companies
Clinical researchers
Pharmaceutical R&D teams
Vesica Health (pilot customer / partner)
Competitors
Lucira Health
Gemelli Biotech
Syros Pharmaceuticals
Chroma Medicine
FOXO Technologies
Chronomics
Epsilen Bio
Scale & contact
Estimated revenue
USD 0 - 1,000,000
Estimated monthly visits
130
Latest news
GenomeWeb · Sep 2025
GenomeWeb reported Epinoma is commercializing EpiAmp, an exclusive-license methylation-preserving amplification chemistry developed at the University of Chicago. The article highlights low-input performance, >99% per-cycle preservation claims, pilot studies with partners such as Vesica Health, and an early-access launch plan.
Polsky Center · Jul 2025
The University of Chicago Polsky Center profile says Epinoma licensed the DNA methylation analysis technology, adapted it into a commercial-grade product, and is positioning EpiAmp for broader research and clinical adoption, including cancer detection and AI-enabled diagnostics.
Jobs and careers at Epinoma
0 jobs at Epinoma
No open positions
Check back later for new openings